EP Patent

EP0400974A2 — Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists

Assigned to Merck and Co Inc · Expires 1990-12-05 · 35y expired

What this patent protects

Substituted Imidazo-fused 6-membered heterocycles of structural formula: <CHEM> wherein A, B, C, and D are independently carbon atoms or nitrogen atoms are angiotensin II antagonists useful in the treatment of hypertension and congestive heart failure.

USPTO Abstract

Substituted Imidazo-fused 6-membered heterocycles of structural formula: <CHEM> wherein A, B, C, and D are independently carbon atoms or nitrogen atoms are angiotensin II antagonists useful in the treatment of hypertension and congestive heart failure.

Drugs covered by this patent

Patent Metadata

Patent number
EP0400974A2
Jurisdiction
EP
Classification
—
Expires
1990-12-05
Drug substance claim
No
Drug product claim
No
Assignee
Merck and Co Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.